The effectiveness of the γδ T cell-originated ADCC against CD19+ ALL was confirmed by employing a CD19 antibody [102], as well as a so-called “triplebody” with two binding sites for CD19 and one for CD16 [103], and a combination of others combination can permit the rapid lysis of leukemic blasts. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.